Bacterial infection profiles in lung cancer patients with febrile neutropenia

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Lanoix, Jean Philippe ^a   Pluquet, Emilie ^b   Lescure, Francois X ^c   Bentayeb, Houcine ^d   Lecuyer, Emmanuelle ^d   Boutemy, Marie ^d   Dumont, Patrick ^e   Jounieaux, Vincent ^a   Schmit, Jean L ^a   Dayen, Charles ^d   Douadi, Youcef ^d  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b Department of Infectious Diseases   (France)

^c HÔPITAL TENON   (France)

^d Department of Pneumology   (France)

^e Chauny Medical Center   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CEFALORIDINE; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; GENTAMICIN; METICILLIN; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; VANCOMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BLOOD CULTURE; DIGESTIVE SYSTEM; DRUG TREATMENT FAILURE; ENTEROBACTERIACEAE; FEBRILE NEUTROPENIA; FEMALE; FRANCE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS; MORTALITY; MULTIDRUG RESISTANCE; RETROSPECTIVE STUDY; RISK FACTOR; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; THROMBOCYTOPENIA; URINARY TRACT; AGED; ANALYSIS OF VARIANCE; BLOOD; CHEMICALLY INDUCED DISORDER; FEVER; LUNG TUMOR; MICROBIOLOGY; MIDDLE AGED; NEUTROPENIA; NONPARAMETRIC TEST; TREATMENT FAILURE;

AGED; ANALYSIS OF VARIANCE; BACTERIAL INFECTIONS; FEMALE; FEVER; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDIES; RISK FACTORS; STATISTICS, NONPARAMETRIC; TREATMENT FAILURE;

EID: 79959535630     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-183     Document Type: Article

References (20)

1. Remontet L. Estimations nationales: tendances de l'incidence et de la mortalité par cancer en France entre 1978 et 2000. 190-193. BEH 41-42/2003.
2. Institut national de prévention et éducation pour la santé Actualités Tabac. N° 2 juin/juillet 1999, Institut national de prévention et éducation pour la santé., http://www.inpes.sante.fr/ta/pdf/tabactu2.pdf
3. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C, . European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006, 42(15):2433-53. 10.1016/j.ejca.2006.05.002, 16750358, European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party.
4. Tjan-Heijnen VC, Postmus PE, Ardizzoni A, Manegold C, Burghouts J. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: An EORTC double-blind placebo controlled phase III study. Ann Oncol 2001, 12:1359-1368. 10.1023/A:1012545507920, 11762805.
5. Cullen M, Steven MD, Billingham L, Gaunt C, Hastings M. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005, 353:988-998. 10.1056/NEJMoa050078, 16148284.
6. Ray-Coquard I. Facteurs pronostics des neutropénies fébriles. Bulletin du Cancer 2006, 93:501-506.
7. Hughes TW, Armstrong D, Bodey GP. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002, 34:730-751. 10.1086/339215, 11850858.
8. Oppenheim BA. The changing pattern of infection in neutropenic patients. J Antimicrob Chemother 1998, 41:7-11. 10.1093/jac/41.suppl_4.7, 9688447.
9. Poyart C, Morand P, Buzyn A. Étiologie des infections bactériennes chez les patients neutropéniques fébriles: rôle du laboratoire dans le diagnostic. Presse Med 2004, 33:460-466. 10.1016/S0755-4982(04)98633-2, 15105768.
10. Cordonnier C, Buzyn A, Leverger G. Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis 2003, 36:149-158. 10.1086/345435, 12522746.
11. Markman M, Abeloff MD. Management of hematologic and infectious complications of intensive induction therapy for small cell carcinoma of the lung. Am J Med 1983, 74:741-746. 10.1016/0002-9343(83)91061-6, 6301275.
12. Matsui K, Masuda N, Takada M, Kusunoki Y, Fukuoka M. A randomized trial comparing imipenem/cilastatine alone with latamoxef plus tobramycin in febrile neutropenic patients with lung cancer. Japan J Clin Oncol 1991, 21:428-434.
13. Niho S, Ohe Y, Goto K. Randomized trial of oral versus intravenous antibiotics in low-risk febrile neutropenic patients with lung cancer. Japan J Clin Oncol 2004, 34:69-73.
14. Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 1999, 341:312-318. 10.1056/NEJM199907293410502, 10423465.
15. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000, 18:3038-51.
16. Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, Ferrant A, Rapoport B, Rolston K, Paesmans M. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 2007, 30S:S51-9.
17. Rikimaru T, Ichiki M, Ookubo Y, Matumoto K, Mimori Y. Pronostic significance of febrile episodes in lung cancer patients receiving chemotherapy. Support Care Cancer 1998, 6:396-401. 10.1007/s005200050183, 9695209.
18. Cometta A, Zinner S, de Bock R, Calandra T, Gaya H. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1995, 39:445-452. 162558, 7726513.
19. Cometta A, Calandra T, Gaya H, Zinner SH, de Bock R. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1996, 40:1108-1115. 163274, 8723449.
20. Berghmans T, Sculier JP, Klastersky J. A prospective study of infections in lung cancer patients admitted to the hospital. Chest 2003, 124:114-120. 10.1378/chest.124.1.114, 12853512.